Public Employees Retirement System of Ohio lessened its holdings in shares of Health Catalyst, Inc. (NASDAQ:HCAT – Free Report) by 76.1% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 18,090 shares of the company’s stock after selling 57,700 shares during the quarter. Public Employees Retirement System of Ohio’s holdings in Health Catalyst were worth $147,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds also recently made changes to their positions in the business. Principal Financial Group Inc. increased its position in Health Catalyst by 6.9% in the 2nd quarter. Principal Financial Group Inc. now owns 29,469 shares of the company’s stock valued at $188,000 after acquiring an additional 1,907 shares during the period. Harbor Capital Advisors Inc. grew its stake in shares of Health Catalyst by 21.3% in the third quarter. Harbor Capital Advisors Inc. now owns 11,764 shares of the company’s stock worth $96,000 after purchasing an additional 2,064 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Health Catalyst by 10.3% during the second quarter. The Manufacturers Life Insurance Company now owns 23,162 shares of the company’s stock valued at $148,000 after purchasing an additional 2,164 shares during the period. Creative Planning raised its stake in shares of Health Catalyst by 13.2% during the third quarter. Creative Planning now owns 21,348 shares of the company’s stock valued at $174,000 after purchasing an additional 2,486 shares in the last quarter. Finally, Quarry LP raised its stake in shares of Health Catalyst by 59.4% during the second quarter. Quarry LP now owns 7,002 shares of the company’s stock valued at $45,000 after purchasing an additional 2,610 shares in the last quarter. Institutional investors own 85.00% of the company’s stock.
Health Catalyst Price Performance
NASDAQ HCAT opened at $7.09 on Friday. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. Health Catalyst, Inc. has a 1 year low of $5.42 and a 1 year high of $11.41. The company has a market cap of $431.41 million, a PE ratio of -5.25 and a beta of 1.31. The stock’s 50-day moving average price is $8.11 and its two-hundred day moving average price is $7.46.
Insider Activity
In other news, insider Linda Llewelyn sold 6,442 shares of the company’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $7.88, for a total value of $50,762.96. Following the transaction, the insider now owns 98,702 shares in the company, valued at $777,771.76. This represents a 6.13 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Kevin Lee Freeman sold 7,500 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $8.94, for a total transaction of $67,050.00. Following the sale, the insider now owns 236,950 shares of the company’s stock, valued at approximately $2,118,333. This represents a 3.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 64,551 shares of company stock worth $532,105 over the last quarter. Corporate insiders own 2.50% of the company’s stock.
Analysts Set New Price Targets
HCAT has been the topic of several research analyst reports. Stephens raised their target price on shares of Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a research note on Thursday, November 14th. Piper Sandler reiterated an “overweight” rating and set a $12.00 price objective (up previously from $11.00) on shares of Health Catalyst in a research note on Tuesday, November 26th. Evercore ISI upped their target price on Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 8th. Citigroup lifted their price target on Health Catalyst from $9.00 to $10.50 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Finally, JPMorgan Chase & Co. upped their price objective on Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a report on Wednesday, September 4th. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, Health Catalyst has an average rating of “Moderate Buy” and an average target price of $11.79.
Read Our Latest Report on Health Catalyst
Health Catalyst Company Profile
Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.
Read More
- Five stocks we like better than Health Catalyst
- What is the Dogs of the Dow Strategy? Overview and Examples
- Oil Titans Face Off: Exxon Mobil or Chevron for 2025 Gains?
- What is the Shanghai Stock Exchange Composite Index?
- Mining Stocks Back in the Spotlight: 3 Key Names to Watch
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- MarketBeat Week in Review – 12/16 – 12/20
Want to see what other hedge funds are holding HCAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Health Catalyst, Inc. (NASDAQ:HCAT – Free Report).
Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.